Updates are available Correction dated 2021-03-23

Article History

Accepted: 16 February 2021

First Online: 15 March 2021

Change Date: 23 March 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41571-021-00503-2

Competing interests

: J.F.G. has served as a compensated consultant or received honoraria from Agios, Amgen, Ariad/Takeda, Array Biopharma, AstraZeneca, Blueprint, Bristol-Myers Squibb (BMS), EMD Serono, Genentech/Roche, Gilead, GlydeBio, Incyte, Loxo Oncology/Lilly, Merck, Mirati, Novartis, Oncorus, Pfizer and Regeneron; has received research support from Ariad/Takeda, Genentech/Roche and Novartis; institutional research support from Adaptimmune, Alexo, Array Biopharma, Blueprint, BMS, Jounce, Merck, Moderna, Novartis and Tesaro; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. G.C. has served on advisory boards for AstraZeneca, Daiichi Sankyo, Ellipsis, Genomic Health, Lilly, Novartis, Roche and Veracyte. S.V.L. has served on advisory boards and/or consulted for Amgen, AstraZeneca, Beigene, Blueprint, BMS, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Inivata, Janssen, Jazz, Lilly, Merck, PharmaMar, Pfizer, Regeneron and Takeda; and declares research grants (to his institution) from Alkermes, AstraZeneca, Bayer, Blueprint, BMS, Corvus, Genentech, Lilly, Lycera, Merck, Merus, Pfizer, Rain, RAPT, Spectrum and Turning Point Therapeutics. B.H. reports research funding (to his institution) from AbbVie, Advaxis, Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Elevation, GlaxoSmithKline, Lilly, Merck, Mirati, Novartis, and Pfizer; and advisory boards consulting roles for Amgen, Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Guardant Health, Merck, Novartis, Pfizer and TPT. R.G. has received honoraria from Regeneron. E.G. has received honoraria for advisory boards, meetings and/or lectures from Adacap, BMS, Celgene, Eisai, Eusa Pharma, Ipsen, Lexicon, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi-Genzyme; and unrestricted research grants from AstraZeneca, Ipsen, Lexicon, MTEM/Threshold, Pfizer and Roche. T.D. declares clinical research support/grants (to his institution) from BMS, Lilly, Exelixis, Holystone, Mirati, Novacure, Pharmacyclics and RAPT Pharma. M.M. has been a consultant for AstraZeneca, Dispersol and Strata Oncology; and has received speaker’s bureau fee from Astellas, AstraZeneca, BMS, Eisai, Janssen, Merck and Seagen N.A. has served as a consultant to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics and Seattle Genetics. S.K. has served as a consultant for Foundation Medicine; has received a speaker’s fee from Roche; has served on advisory boards for Pfizer; and has received research funding from ACT Genomics, Konica Minolta, OmniSeq and Sysmex. P.M.K. has served as a consultant and/or advisory board member for Foundation Medicine, Ipsen, Natera, QED and Taiho Oncology; and declares clinical trials involvement and/or funding from AstraZeneca, Boston Scientific and TerSera. H.P. declares research funding/grant support for clinical trials (to her institution) from Ambrx, Amgen, Aprea Therapeutics, Array BioPharma, Bayer, BeiGene, BJ Bioscience, BMS, Daiichi Sankyo, Elicio Therapeutics, Lilly, EMD Serono, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Hoffman-LaRoche, Hutchison MediPharma, ImmuneOncia Therapeutics, Incyte, Jounce, Mabspace Biosciences, MacroGenics, MedImmune, Medivation, Merck, Millennium, Mirati Therapeutics, Novartis Pharmaceuticals, Oncologie, Pfizer, PsiOxus Therapeutics, Puma Biotechnology, Regeneron Pharmaceuticals, Seattle Genetics, Synermore Biologics, Taiho Pharmaceutical, TopAlliance Biosciences, Turning Point Therapeutics, Vedanta Biosciences, Vertex Pharmaceuticals and Xencor. T.K.C. reports institutional and personal research support from Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Calithera, Cerulean, Corvus, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products, Sanofi/Aventis, Takeda and Tracon; honoraria from Alexion, American Society of Medical Oncology, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Cerulean, Clinical Care Options, Corvus, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Harborside Press, Heron Therapeutics, Ipsen, <i>Kidney Cancer Journal</i>, <i>Lancet Oncology</i>, Lilly Oncology, L-path, Merck, Michael J. Hennessy (MJH) Associates (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Navinata Healthcare, NCCN, <i>New England Journal of Medicine</i>, Novartis, Peloton, Pfizer, Platform Q, Prometheus Labs, Research to Practice, Roche, Roche Products, Sanofi/Aventis and Up-to-Date; consulting or advisory roles with Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Cerulean, Corvus, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Lilly Ventures, Merck, NCCN, Novartis, Peloton, Pfizer, Pionyr, Prometheus Labs, Roche, Sanofi/Aventis, Tempest and Up-to-Date; stock/option ownership in Pionyr and Tempest; present or past leadership roles as Director of GU Oncology Division at the Dana-Farber Cancer Institute (DFCI) and past President of Medical Staff at DFCI, a member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, a member of the KidneyCan Advisory board, Kidney Cancer Research Summit co-chair (2019–present); patents, royalties or other intellectual properties related to biomarkers of immune checkpoint blockers and circulating free methylated DNA; and travel, accommodation, expenses, in relation to consulting, advisory roles or honoraria. N.P. serves on the ASH Communications and ASCO Leukemia advisory panels; has received consultant fees from Blueprint, BMS, ImmunoGen, Pacylex Pharmaceuticals; grants from Affymetrix and the Sagerstrong Foundation; honoraria from AbbVie, Blueprint, Celgene, DAVA Oncology, Incyte, LFB Biotechnologies, MustangBio, Novartis, Roche Diagnostics, Springer Science & Business Media and Stemline Therapeutics; research support from AbbVie, Affymetrix, Celgene, Cellectis, Daiichi Sankyo, Novartis, Plexxikon, Samus Therapeutics and Stemline Therapeutics; and travel support from AbbVie, Celgene, DAVA Oncology, MustangBio and Stemline Therapeutics. V.S. declares research funding/grant support for clinical trials (to his institution) from AbbVie, Agensys, Alfa-Sigma, Altum, Amgen, Bayer, Berghealth, Blueprint, Boston Biomedical, Boston Pharmaceuticals, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharma, Incyte, Inhibrx, Loxo oncology, MedImmune, Multivir, NCCN, Novartis, Pharmamar, Pfizer, Takeda and Turning Point Therapeutics; has received travel funding from ASCO, ESMO, Helsinn, Incyte, Novartis and Pharmamar; and has served on advisory boards for AstraZeneca/MedImmune, Helsinn, Incyte, Loxo Oncology/Lilly, Novartis, QED Pharma, R-Pharma US and Signant Health. The other authors declare no competing interests.

Free to read: This content has been made available to all.